Feed XOMAP
XO

XOMA Royalty Corporation XOMAP · NASDAQ

$24.98 +0.00% (+$0.00)

Summary

55 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 61 USD is left as net profit.
  • Revenue grew by 105% a year over the last 3 years.
  • The share price is below the Bulios Fair Price.
  • It bought back its own shares for $16.0M in the last fiscal year, 5.3% of its market value.

What to watch

  • Operating profit does not even cover the interest on its debt.
  • It earns only 4.5 USD a year on every 100 USD of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $24.98
Biotechnology industry median
P/E today 9.5

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 9.5 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 105% a year.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

High, stretched
Yield
8.63%
Paid out of profit
82%

You receive $2.16 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

56% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.